Biomedical Engineering Reference
In-Depth Information
base case launch years in the US
Breast
2000
2005
2015
2020
2010
Lung
2000
2005
2010
2015
2020
Key
MAbs
Vaccines
Anti-Angiogenesis
Kinase Inhibitors
Apoptosis Inducers
Anti-Sense
Gene Therapy
Colorectal
2000
2005
2010
2015
Prostate
2000
2005
2015
2020
2010
Fig. 2. Predicted new drug application (NDA) dates for molecular therapies in the USA. The years
2005-2010 will see an explosion of novel therapies coming into clinical use outside of the research
setting (MAb
=
molecular antibodies).
therapies will be used across a range of cancers. In the future, it will be important to
know whether a person's cancer has particular biological or genetic characteristics.
Traditional categories will continue to be broken down, and genetic profiling will
enable treatments to be targeted towards the right patients. Patients will understand
that their treatment options depend on their genetic profile. The risks and benefits
of treatment will be much more predictable than they are today (Table 5).
Therapies will emerge through our knowledge of the human genome and the
use of sophisticated bioinformatics. Targeted imaging agents will be used to deliver
therapy at the time of screening or diagnosis. The way that cancer patients are
monitored will also change, as technology allows for closer tracking of the dis-
ease process. Treatment strategies will reflect this, and drug resistance will become
Table 5.
Drivers of molecular therapeutics.
HGP and bioinformatics
Expression vectors for target production
In silico
drug design
Robotic high throughput screening
Combinatorial chemistry
Platform approach to drug discovery
Huge increase in number of molecular targets
Search WWH ::
Custom Search